Edition:
India

Vermillion Inc (VRML.OQ)

VRML.OQ on NASDAQ Stock Exchange Capital Market

1.47USD
16 Feb 2018
Change (% chg)

$0.03 (+2.08%)
Prev Close
$1.44
Open
$1.46
Day's High
$1.49
Day's Low
$1.41
Volume
12,739
Avg. Vol
15,955
52-wk High
$2.85
52-wk Low
$1.03

Latest Key Developments (Source: Significant Developments)

Vermillion Appoints Bob Beechey To Newly Created CFO Post
Tuesday, 19 Dec 2017 

Dec 19 (Reuters) - Vermillion Inc ::VERMILLION APPOINTS BOB BEECHEY TO NEWLY CREATED CFO POST.VERMILLION - MOST RECENTLY, BEECHEY WAS VICE PRESIDENT AND GENERAL MANAGER OF Q SQUARED SOLUTIONS BIOANALYTICAL, ADME LABORATORY OPERATIONS.  Full Article

Vermillion reports third quarter loss of $0.06 per share
Thursday, 9 Nov 2017 

Nov 8 (Reuters) - Vermillion Inc :Vermillion reports third quarter 2017 results.Q3 revenue rose 12 percent to $699,000.Qtrly net loss per share attributable to common stockholders basic and diluted $0.06‍​.  Full Article

‍Aspira Labs says has entered into agreements to provide coverage for OVA1​
Friday, 27 Oct 2017 

Oct 27 (Reuters) - Vermillion Inc :‍Aspira Labs says has entered into agreements to provide coverage for its in vitro diagnostic test, OVA1​.‍Aspira Labs- agreements with JVHL , QCA Health Plan of Arkansas, Louisiana State Medicaid Program, and Arizona State Medicaid Program​.  Full Article

Vermillion files for mixed shelf of up to $50 mln - SEC filing
Wednesday, 25 Oct 2017 

Oct 24 (Reuters) - Vermillion Inc :Vermillion files for mixed shelf of up to $50 million - SEC filing.  Full Article

Vermillion reports Q2 loss per share $0.07
Wednesday, 10 Aug 2016 

Vermillion Inc : Vermillion reports second quarter 2016 results . Q2 loss per share $0.07 .Q2 revenue $709,000 versus $535,000.  Full Article

Vermillion Inc Q1 loss per share $0.09
Tuesday, 17 May 2016 

Vermillion Inc : Expect net cash utilization of $2.0 million - $3.0 million in q2 of 2016 . Vermillion reports first quarter 2016 results .Q1 loss per share $0.09.  Full Article

Vermillion, Inc announces FDA Clearance of Overa®
Monday, 21 Mar 2016 

Vermillion, Inc:Says Receipt of 510(k) marketing clearance from the FDA for successor to Vermillion's OVA1® test for determining ovarian cancer risk in conjunction with independent clinical and imaging assessment prior to planned surgery for a women with a pelvic mass.Says Second Generation OVA1 test, previously referred to as "OVA2", has been trademarked "Overa®.Overa replaces two of the five OVA1 biomarkers with HE4 and FSH in order to improve specificity and reduce the need for physicians to determine menopausal status when interpreting the test.  Full Article

BRIEF-Vermillion Announces Agreement With Bluecross Blueshield Of Illinois

* VERMILLION ANNOUNCES AGREEMENT WITH BLUECROSS BLUESHIELD OF ILLINOIS Source text for Eikon: Further company coverage: